MicroRNA-31 Reduces the Motility of Proinflammatory T Helper 1 Lymphocytes

Markus Bardua, Claudia Haftmann, Pawel Durek, Kerstin Westendorf, Antje Buttgereit, Cam Loan Tran, Mairi McGrath, Melanie Weber, Katrin Lehmann, Richard Addo, Gitta Anne Heinz, Anna‐Barbara Stittrich, Patrick Maschmeyer, Helena Radbruch, Michael Lohoff, Hyun‐Dong Chang, Andreas Radbruch, Mir‐Farzin MashreghiFrontiers in Immunology 2018 · DOI

TL;DR

This study reveals that microRNA-31 (miR-31) plays a crucial role in controlling the migration of pro-inflammatory T helper 1 (Th1) cells, which are implicated in chronic inflammatory diseases like rheumatoid arthritis. By downregulating miR-31, researchers were able to increase the motility of these cells, suggesting a potential therapeutic avenue for managing inflammatory conditions.

What Problem Does This Paper Address?

Chronic inflammation, particularly in rheumatic diseases, is often driven by the accumulation and persistence of specific immune cells called proinflammatory T helper 1 (Th1) cells within inflamed tissues. While we know these cells are key players, the precise molecular mechanisms that govern their movement and retention within these problematic sites remain unclear. Understanding these mechanisms is critical for developing strategies to dislodge these cells and resolve chronic inflammation. This paper aims to uncover how Th1 cells are regulated in their migratory behavior, focusing on the role of microRNAs.

Methods

The researchers employed a multi-pronged approach:

  • In vitro cell culture: They generated and manipulated Th1 cells from mice, including repeatedly activated Th1 cells (Th1 rep) and naive Th1 cells.
  • MicroRNA analysis: They used quantitative real-time PCR (qRT-PCR) to measure miR-31 expression levels in different Th cell subsets and in cells isolated from patients.
  • Gene expression analysis: RNA sequencing (RNA-seq) and microarray analysis were used to identify genes affected by miR-31 modulation.
  • Functional assays: Transwell migration assays and adhesion assays were performed to assess the migratory capacity and adherence of Th1 cells.
  • Gene regulatory network analysis: They used bioinformatics tools like TargetScanMouse and STRING to predict and visualize interactions between miR-31, its target genes, and key signaling pathways.
  • Inhibition and overexpression studies: They used antagomirs to inhibit miR-31 and siRNA to knock down transcription factors like FOXO1. They also used retroviral vectors to overexpress a constitutively active form of FOXO1.
  • Transcription factor analysis: Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data was analyzed to identify binding sites of key transcription factors (T-bet, FOXO1, STAT1, STAT4) in the miR-31 promoter region.

Datasets

The study utilized several datasets:

  • Murine Th1 cells: Generated in vitro from C57BL/6, BALB/c, and OTII mice.
  • Human patient samples: Synovial fluid from patients with rheumatoid arthritis (RA) and peripheral blood from healthy donors.
  • Publicly available ChIP-seq data: Data for p300, H3K4me3, H3K27me3, STAT1, STAT4, T-bet, and FOXO1 in Th1 cells and naive CD4+ T cells.
  • RNA-seq data: Generated by the authors from Th1 rep cells and deposited in the Gene Expression Omnibus (GEO) database (accession no. GSE122218).
  • Microarray data: Generated by the authors from Th1 rep cells and deposited in the GEO database (accession no. GSE122223).

Key Insights and Ideas

  • miR-31 as a "brake" on Th1 cell motility: The most striking finding is that miR-31 acts as a negative regulator of Th1 cell migration. When miR-31 levels are high, these cells move less.
  • Upregulation in disease and chronic inflammation: miR-31 is significantly increased in Th1 cells that have been repeatedly activated (mimicking chronic inflammation) and in memory Th cells from the joints of RA patients. This suggests its role is particularly relevant in sustained inflammatory responses.
  • Targeting cytoskeletal machinery: miR-31 exerts its effect by downregulating genes involved in cytoskeletal rearrangement and cell motility, including those in the PI3K and actin cytoskeleton pathways.
  • A T-bet and FOXO1 regulatory axis: The study uncovers a critical regulatory network where the Th1 master transcription factor T-bet promotes miR-31 expression, while the transcription factor FOXO1 represses it. This interplay is key to controlling Th1 cell behavior.
  • Implications for therapeutic intervention: The ability to increase Th1 cell motility by inhibiting miR-31 opens up possibilities for therapies aimed at flushing these inflammatory cells out of affected tissues.

Key Results

  • miR-31 is upregulated: Murine Th1 rep cells showed a 3.2-fold increase in miR-31 expression compared to once-activated Th1 cells. Human RA patient memory Th cells exhibited even higher levels (8.4-fold ex vivo).
  • miR-31 inhibition increases migration: Blocking miR-31 with antagomirs in Th1 rep cells led to a significant increase in their migratory capacity towards CXCL10, partially rescuing the reduced motility observed in repeatedly activated cells.
  • Target gene enrichment: After 72 hours of miR-31 inhibition, gene set enrichment analysis (GSEA) revealed significant enrichment of genes involved in "Phosphatidylinositol 3-kinase signaling system" and "Regulation of actin cytoskeleton."
  • T-bet promotes, FOXO1 represses miR-31: TCR activation and IFN-γ induced miR-31 expression, with T-bet acting as a positive regulator. Conversely, FOXO1 was found to bind to the miR-31 promoter and inhibit its expression.
  • FOXO1 inactivation is necessary for high miR-31: Inactivation of FOXO1 (via overexpression of a constitutively active form or TGF-β treatment) led to increased miR-31 expression and reduced T-bet levels.

Limitations and Future Work

  • In vitro model: The study primarily uses in vitro generated Th1 cells as a model for inflamed tissue-resident Th cells. While this model is well-justified, future work could involve in vivo studies using conditional miR-31 knockout mice or humanized models to confirm these findings in a more complex biological setting.
  • Reporter assays: While the study identified putative miR-31 targets and showed their expression changes, direct experimental validation using luciferase reporter assays for specific targets is suggested for definitive proof of direct regulation.
  • Chronic inflammation setting: The authors propose evaluating miR-31 function in a chronic inflammatory setting, potentially through transferring human Th cells into a humanized model of arthritis.
  • Therapeutic potential: The authors suggest that antagomir-based reduction of miR-31 could be a novel approach to mobilize therapy-resistant proinflammatory Th1 cells from inflamed tissues, potentially resolving chronic inflammation. This warrants further investigation into its therapeutic efficacy and safety.

Summary updated

Abstract

Proinflammatory type 1 T helper (Th1) cells are enriched in inflamed tissues and contribute to the maintenance of chronic inflammation in rheumatic diseases. Here we show that the microRNA- (miR-) 31 is upregulated in murine Th1 cells with a history of repeated reactivation and in memory Th cells isolated from the synovial fluid of patients with rheumatic joint disease. Knock-down of miR-31 resulted in the upregulation of genes associated with cytoskeletal rearrangement and motility and induced the expression of target genes involved in T cell activation, chemokine receptor- and integrin-signaling. Accordingly, inhibition of miR-31 resulted in increased migratory activity of repeatedly activated Th1 cells. The transcription factors T-bet and FOXO1 act as positive and negative regulators of T cell receptor (TCR)-mediated miR-31 expression, respectively. Taken together, our data show that a gene regulatory network involving miR-31, T-bet, and FOXO1 controls the migratory behavior of proinflammatory Th1 cells.
BibTeX
@inproceedings{bardua2018microrna,
  author = {Markus Bardua and Claudia Haftmann and Pawel Durek and Kerstin Westendorf and Antje Buttgereit and Cam Loan Tran and Mairi McGrath and Melanie Weber and Katrin Lehmann and Richard Addo and Gitta Anne Heinz and Anna‐Barbara Stittrich and Patrick Maschmeyer and Helena Radbruch and Michael Lohoff and Hyun‐Dong Chang and Andreas Radbruch and Mir‐Farzin Mashreghi},
  title = {{MicroRNA-31 Reduces the Motility of Proinflammatory T Helper 1 Lymphocytes}},
  booktitle = {Frontiers in Immunology},
  year = {2018},
  doi = {10.3389/fimmu.2018.02813},
}
Figure